Tarabios develops a point-of-care coagulometer that enables patients on Warfarin therapy to monitor their blood clotting times at home using fresh or citrated whole blood. This handheld device enhances patient self-care and improves the efficiency of healthcare professionals by providing timely and accurate coagulation data.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients on Warfarin therapy require frequent monitoring of blood clotting times to ensure proper dosage and prevent complications. Traditional lab testing can be inconvenient, time-consuming, and costly, hindering timely adjustments and potentially leading to adverse events.
Solution
Tarabios is developing a point-of-care coagulometer that allows patients on Warfarin to conveniently monitor their blood clotting times at home. The handheld device uses fresh or citrated whole blood to provide timely and accurate coagulation data. This enables enhanced patient self-care, more efficient healthcare professional oversight, and potentially reduces the risk of complications associated with infrequent monitoring. The underlying technology is also being developed for multiplexed, low-cost point-of-need tests for cardiac markers, sexually transmitted diseases, hepatitis, tuberculosis, and other infectious diseases.
Target Audience
The primary target audience includes patients on Warfarin therapy requiring regular blood coagulation monitoring, as well as healthcare professionals seeking to improve patient self-care and monitoring efficiency.
Features
- Handheld, portable coagulometer for point-of-care testing
- Compatible with fresh or citrated whole blood samples
- Provides rapid and accurate blood clotting time measurements
- Potential for future expansion to multiplexed testing for various diseases
- Proprietary technology with intellectual property protection